Disposition of 120000 shares by Hollander David of Revance subject to Rule 16b-3 Filed transaction by Revance Officer: Cmo & Global Therapeutics Lead. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Disposition of 120000 shares by Hollander David of Revance subject to Rule 16b-3

RVNCDelisted Stock  USD 3.65  0.00  0.00%   
About 56% of Revance Therapeutics,'s investor base is looking to short. The analysis of current outlook of investing in Revance Therapeutics, suggests that many traders are alarmed regarding Revance Therapeutics,'s prospects. The current market sentiment, together with Revance Therapeutics,'s historical and current headlines, can help investors time the market. In addition, many technical investors use Revance Therapeutics, stock news signals to limit their universe of possible portfolio assets.
  
Filed transaction by Revance Officer: Cmo & Global Therapeutics Lead. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Read at thelincolnianonline.com
news
  
Revance insider trading alert for disposition of performance stock units by Hollander David, Officer: Cmo & Global Therapeutics Lead, on 8th of November 2024. This event was filed by Revance with SEC on 2025-02-15. Initial filing of beneficial ownership - SEC Form 3

Revance Therapeutics, Fundamental Analysis

We analyze Revance Therapeutics,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Revance Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Revance Therapeutics, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Working Capital

Working Capital Comparative Analysis

Revance Therapeutics, is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Revance Therapeutics, Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Revance Therapeutics, stock to make a market-neutral strategy. Peer analysis of Revance Therapeutics, could also be used in its relative valuation, which is a method of valuing Revance Therapeutics, by comparing valuation metrics with similar companies.

Peers

Revance Therapeutics, Related Equities

PLRXPliant Therapeutics   4.65   
0%
47.0%
DMACDiaMedica Therapeutics   2.46   
0%
25.0%
TERNTerns Pharmaceuticals   1.32   
0%
13.0%
ETNB89bio   0.76   
0%
7.0%
STOKStoke Therapeutics   0.75   
0%
7.0%
DAWNDay One   0.64   
0%
6.0%
VTYXVentyx Biosciences   0.57   
0%
5.0%
MDGLMadrigal Pharmaceuticals   0.26   
2.0%
0%
APLSApellis Pharmaceuticals   0.53   
5.0%
0%
NUVLNuvalent   1.16   
11.0%
0%
ACLXArcellx   1.29   
13.0%
0%
AKROAkero Therapeutics   1.48   
15.0%
0%
IMCRImmunocore Holdings   1.72   
17.0%
0%
BPMCBlueprint Medicines   6.11   
62.0%
0%
AMLXAmylyx Pharmaceuticals   9.79   
100.0%
0%
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.

Other Consideration for investing in Revance Stock

If you are still planning to invest in Revance Therapeutics, check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Revance Therapeutics,'s history and understand the potential risks before investing.
Transaction History
View history of all your transactions and understand their impact on performance
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios